We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what?

Jason GrebelySusan MatthewsLouise M. CauserJordan J. FeldPhilip CunninghamGregory J. DoreTanya L. Applegatea The Kirby Institute,UNSW,Sydney,New South Wales,Australiab Flinders University International Centre for Point-of-Care Testing,Flinders Health and Medical Research Institute,Flinders University,Bedford Park,South Australia,Australiac Toronto Centre for Liver Disease,Toronto General Hospital,Toronto,Canadad NSW State Reference Laboratory for HIV,St Vincent's Centre for Applied Medical Research,Sydney,New South Wales,Australia

DOI: https://doi.org/10.1080/14737159.2023.2292645

2024-01-04

Expert Review of Molecular Diagnostics

Abstract:Introduction Progress toward hepatitis C virus (HCV) elimination is impeded by low testing and treatment due to the current diagnostic pathway requiring multiple visits leading to loss to follow-up. Point-of-care testing technologies capable of detecting current HCV infection in one hour are a 'game-changer.' These tests enable diagnosis and treatment in a single visit, overcoming the barrier of multiple visits that frequently leads to loss to follow-up. Combining point-of-care HCV antibody and RNA tests should improve cost-effectiveness, patient/provider acceptability, and testing efficiency. However, implementing HCV point-of-care testing programs at scale requires multiple considerations.

pathology